Algernon obtains $4M financing for Alzheimer's clinics

Executive Summary

• Algernon Pharmaceuticals Inc. (soon to be Algernon Health Inc.) has entered into a definitive agreement with Catalyst MedTech to acquire four FDA-cleared CareMiBrain PET scanner systems for approximately CAD $4 million.
• The transaction is structured as a non-dilutive financing deal, requiring a 20% deposit and monthly payments at an average annual interest rate of 7%, with a balloon payment due after two years.
• The scanners will be deployed in four new, dedicated neuroimaging clinics in the U.S. focused on the early detection of Alzheimer's disease and other neurological disorders, addressing a market gap created by recent FDA approvals for Alzheimer's therapies.

Key Details

• Transaction Value & Structure:
  • Total value of the definitive equipment order and financing agreement is over CAD $4 million.
  • Financing terms include a 20% deposit by Algernon.
  • Monthly payments carry an average annual interest rate of 7%.
  • A balloon payment is owing after two years of operations.
  • The deal includes an option to acquire an additional six systems for future clinic expansion on an adjusted cost basis.
• Equipment Specifications (Oncovision CareMiBrain):
  • Stand-alone PET system without integrated CT, reducing patient radiation exposure by up to 25% compared to full-body PET/CT units.
  • Ultrahigh-resolution with less than 1.6-millimetre spatial resolution.
  • FDA-cleared for amyloid and tau imaging in over 600 patients.
  • Ergonomic reclining chair design with ultrafast acquisition times.
  • Low power requirements (standard wall outlet 115-240V) and small footprint (approx. 8ft x 13ft).
• Operational Plan:
  • Establishment of four dedicated, brain-specific PET neuroimaging clinics in the U.S.
  • Clinics will focus on early-stage Alzheimer's detection, as well as dementia, epilepsy, neuro-oncology, and movement disorders.
  • Each PET brain scan is priced at approximately $5,000 (U.S.), covered by private insurance, Medicare, and Medicaid.
  • Catalyst MedTech will provide consulting services on clinical solutions, regulatory compliance, accreditation, billing, coding, and warranty/services contracts.
• Strategic Context:
  • Algernon recently announced a name change to Algernon Health Inc. to reflect its pivot toward Alzheimer's diagnostics and neuroimaging clinics.
  • The move capitalizes on the recent U.S. FDA approval of two new Alzheimer's antibody therapies, which require brain-specific PET scans (or spinal taps) prior to treatment initiation.
  • The U.S. market currently lacks sufficient full-body PET/CT scanners dedicated to brain imaging, with 45% of existing scanners located in hospitals and prioritized for cancer and cardiac imaging.

Notable Quotes

• Christopher J. Moreau, CEO of Algernon: "We are pleased to be working with Catalyst MedTech and acquiring this groundbreaking technology for our planned neuroimaging clinics, which improves patient access and experience, and reduces radiation exposure by up to 25 per cent compared to full-body PET/CT units currently in use... Catalyst MedTech's extensive experience in nuclear medicine... will dramatically assist us in fully realizing our new neuroimaging initiative effectively and efficiently."
• Martin Shirley, CEO of Catalyst MedTech: "We have been very impressed with Algernon's management team as well as their visionary commitment to provide these new optimized brain PET scanners by way of pioneering, stand-alone, brain imaging medical clinics across the U.S."